The European biosimilars market is poised for robust growth, projected to expand at a compound annual growth rate (CAGR) of 15.4% from 2024 to 2031. This growth is expected to elevate the market from a value of USD 12.3 billion in 2024 to an impressive USD 33.5 billion by 2031. The significant surge in the market is driven by the increasing adoption of biosimilars across diverse therapeutic areas, especially oncology. Rising healthcare costs are spurring demand for more affordable treatment alternatives, thus contributing to the growing preference for biosimilars. The market’s expansion is further facilitated by the increasing acceptance and competition among biosimilar products, which are enhancing access to vital therapies while also improving treatment outcomes across European healthcare systems.
Key Industry Highlights
The biosimilars market in Europe is witnessing substantial progress due to several key factors. A prominent trend includes the increasing patent expirations of biologic drugs, which are paving the way for the entry of cost-effective biosimilars. Furthermore, the growing preference for affordable biosimilar alternatives to expensive originator biologics in therapeutic indications like autoimmune diseases, diabetes, and inflammatory conditions is propelling market growth. Additionally, a robust regulatory environment, with regulatory agencies like the European Medicines Agency (EMA) playing a pivotal role, is contributing to market development by ensuring biosimilars meet high safety and efficacy standards. With more digital strategies employed by biosimilar manufacturers, market reach is also expanding, further broadening consumer bases.
Get a Sample Copy of Research Report (Use Corporate Mail id for Quick Response): https://www.persistencemarketresearch.com/samples/34923
Market Dynamics
Drivers
Patent Expirations of Biologics: The expiration of patents for several blockbuster biologics is one of the major drivers for biosimilars in Europe. Once patents expire, biosimilar manufacturers can introduce affordable alternatives to these high-cost therapies, making them a more accessible option for healthcare providers and patients.
Cost-Effectiveness: Healthcare systems across Europe are under pressure to contain costs, and biosimilars offer significant savings over originator biologics. The cost-effective nature of biosimilars has resulted in their adoption across therapeutic areas, particularly in oncology, rheumatology, and immunology.
Regulatory Support: The EMA has streamlined the approval process for biosimilars, ensuring they meet rigorous standards while promoting faster market entry. This regulatory support has contributed to increasing physician confidence in biosimilars and boosting adoption rates.
Restraints
Patent and Intellectual Property Issues: Biosimilar manufacturers often face intellectual property (IP) challenges, especially concerning patent litigation initiated by originator biologics. Complex patent portfolios and strategies like “evergreening” can delay market entry for biosimilars, hindering their ability to offer cost-effective alternatives in a timely manner.
Slow Adoption in Some Regions: Despite strong regulatory frameworks, the adoption of biosimilars is still slow in some European countries. Factors such as conservative prescribing practices, lack of awareness among healthcare professionals, and cultural hesitations are contributing to the reluctance of some regions to fully embrace biosimilars.
Opportunities
Biosimilar-Reference Biologic Switching: The potential to switch patients from originator biologics to biosimilars presents a significant opportunity for market growth. As healthcare systems focus more on cost-effective treatment options, the smooth transition between biologics and biosimilars could further reduce healthcare costs while improving patient access to affordable therapies.
Expansion into Non-Oncology Therapeutic Areas: While oncology has been the dominant focus for biosimilars, the expansion into non-oncology areas like autoimmune diseases, diabetes, and inflammatory conditions presents a large growth opportunity. These therapeutic areas represent vast patient populations and high unmet needs for affordable biologic therapies.
Category-Wise Analysis
Oncology Segment
Oncology is projected to dominate the biosimilars market in Europe, with an expected CAGR of 13.7% by 2031. The increasing burden of cancer, coupled with the high cost of biologic oncology treatments, is driving demand for biosimilars in this area. Biosimilars offer patients effective, safe, and affordable alternatives to branded biologics. Furthermore, the strong regulatory support for oncology biosimilars and favorable reimbursement policies are expected to contribute significantly to their adoption.
Hospital Pharmacies Segment
The hospital pharmacies segment is expected to showcase a CAGR of 14.2% through 2031. Hospital pharmacies are key distribution channels for biosimilars, particularly in the administration of oncology and chronic disease treatments. The shift towards cost-efficient therapies, along with the central role of hospitals in drug distribution, supports this growth trajectory. As more biosimilars become available, hospital pharmacies will continue to be a critical player in ensuring patients have access to affordable treatment options.
Request for Customization of the Research Report: https://www.persistencemarketresearch.com/request-customization/34923
Regional Insights
Germany is set to remain a leader in the European biosimilars market, with a projected CAGR of 15% through 2031. The country has a well-established regulatory and reimbursement framework, making it an ideal environment for the widespread use of biosimilars. Notably, in 2019, Germany implemented a law for the automatic substitution of injectable biologics with biosimilars, further cementing its position as a hub for biosimilar adoption in Europe. Other key countries contributing to market growth include the UK, France, and Italy, with growing acceptance of biosimilars driven by regulatory and cost-saving initiatives.
Competitive Landscape
The European biosimilars market is highly competitive, with both established pharmaceutical companies and specialized biosimilar manufacturers vying for market share. Leading players include Sandoz, Amgen, Biogen, Celltrion, and Samsung Biologics, among others. These companies have strong R&D capabilities, regulatory expertise, and extensive distribution networks, which enable them to maintain their leadership positions in the market.
Emerging players are also making their mark, with companies like Biocon and Viatris capitalizing on the growing demand for biosimilars. Competition is expected to intensify as more players enter the market, driven by the rising demand for affordable biologic treatments. Pricing strategies, product quality, and safety will continue to be key differentiating factors in this rapidly evolving market.
Key Players
Sandoz
Amgen
Biogen
Celltrion
Samsung Bioepis
Pfizer
Biocon
Viatris
Coherus BioSciences
Boehringer Ingelheim
Eli Lilly and Company
Bio-Thera Solutions
Market Segmentation
The Europe biosimilars market can be segmented based on product type, therapeutic area, distribution channel, and geography. By product type, the market includes monoclonal antibodies, insulin, and other biologic drugs. By therapeutic area, oncology, immunology, and endocrinology are the dominant categories. Distribution channels include hospital pharmacies, retail pharmacies, and online pharmacies.
Recent Developments
In July 2024, the Committee for Medicinal Products for Human Use (CHMP) recommended 14 biosimilars for approval by the EMA. These included products from Samsung Bioepis, Formycon, and Fresenius Kabi, showcasing the continuous growth and innovation in the biosimilars sector. Furthermore, in a major development, Apotex Inc. partnered with Coherus Biosciences to license toripalimab, an anti-PD-1 monoclonal antibody, marking its entry into the oncology biosimilars market.
Future Outlook
The future of the Europe biosimilars market is promising, driven by strong regulatory support, cost containment pressures, and a growing emphasis on value-based healthcare models. With more biologic patents expiring in the coming years, the market is set for further expansion, particularly in oncology and other therapeutic areas such as autoimmune diseases and diabetes. The increasing role of hospital pharmacies in biosimilar distribution and the potential for biosimilar-reference biologic switching offer exciting growth opportunities. As physician confidence grows and the regulatory landscape continues to evolve, biosimilars are expected to become an integral part of the healthcare ecosystem in Europe, providing patients with access to safe, effective, and affordable biologic therapies.
In conclusion, the Europe biosimilars market is on a strong growth trajectory, backed by favorable regulatory environments, increasing healthcare demands, and cost-saving opportunities. The next decade promises continued innovation, greater accessibility, and significant savings for healthcare systems across the region.
